Disclosure under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ( SEBI Listing Regulations ) ESG Rating
PPLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Piramal Pharma has been assigned an ESG (Environment, Social, and Governance) rating of 61 by NSE Sustainability Ratings and Analytics Limited for FY 2023-24. The rating was based on ESG-related data made publicly available by the company for that financial year. Importantly, Piramal Pharma clarified that it did not engage NSE Sustainability for this rating — the agency prepared the report voluntarily based on publicly disclosed information. The disclosure is being made under Regulation 30 of SEBI Listing Regulations and has also been uploaded on the company's website.
A score of 61 suggests moderate ESG performance. While this is a routine regulatory disclosure with no immediate financial impact, it may be referenced by ESG-focused institutional investors. The voluntary nature of the rating means it should be interpreted with appropriate context.